FoxO1 in Gestational Diabetes

FoxO1 在妊娠糖尿病中的作用

基本信息

项目摘要

Abstract: Gestational diabetes mellitus (GDM) is characterized by glucose intolerance in pregnant women without previously diagnosed diabetes. GDM affects up to 10% of all pregnancies, imposing a significant adverse effect on the health of both mother and fetus. To date, the underlying mechanism of GDM remains elusive. Pregnancy is commonly associated with insulin resistance in the mother, a physiological response that serves to spare blood glucose supplies for the fetus. To overcome insulin resistance, pancreatic β-cells of pregnant mothers release more insulin into the blood. Such an adaptive response, termed “β-cell compensation”, is essential for maintaining normal blood glucose metabolism in pregnancies. In at-risk pregnant women, β-cells fail to compensate for maternal insulin resistance, contributing to insulin insufficiency and GDM. Nonetheless, how β-cells compensate for maternal insulin resistance during pregnancy and what causes β-cell failure in GDM are poorly understood. To decipher the mechanism of β-cell compensation for pregnancy, we determined gestational regulation of β-cell mass and function by FoxO1 - a key transcription factor that integrates insulin signaling and nutritional cues to cell metabolism, survival, proliferation and differentiation. We found that β-cell FoxO1 expression is markedly upregulated, coinciding with the physiological induction of β-cell compensation in mice during pregnancy. Furthermore, we showed that β-cell FoxO1 deficiency predisposes pregnant female mice to GDM, as evidenced by the induction of impaired glucose tolerance, elevated blood glucose levels and reduced glucose-stimulated insulin secretion during pregnancy. These new data underscore the importance of FoxO1 in governing the adaptive changes of β-cell mass and function in response to pregnancy, spurring the hypothesis that FoxO1 deregulation may be the missing link between maternal insulin resistance and β-cell decompensation in GDM. To address this hypothesis, we will use rigorous in vivo and ex vivo studies to characterize the role of FoxO1 in integrating gestational hormonal signaling to adaptive changes in β-cell mass and function during pregnancy. We will determine the mechanism by which FoxO1 augments β-cell compensation for maternal insulin resistance in female mice. Furthermore, we will determine the mechanism of how β-cell FoxO1 deficiency causes β-cell decompensation, contributing to the development of GDM. Accomplishing this project will deepen our understanding of gestational β-cell compensation for maternal insulin resistance, providing new mechanistic insights into β-cell decompensation and GDM.
摘要: 妊娠期糖尿病(GDM)的特征是无糖代谢异常的孕妇 之前被诊断为糖尿病。妊娠期糖尿病影响高达10%的怀孕,造成严重的不利影响 对母亲和胎儿的健康都有影响。到目前为止,GDM的潜在机制仍然难以捉摸。 怀孕通常与母亲的胰岛素抵抗有关,这是一种生理反应, 为胎儿提供充足的血糖。为克服胰岛素抵抗,孕妇胰腺β细胞 母亲会向血液中释放更多的胰岛素。这种自适应反应被称为“β-cell补偿”, 在怀孕期间维持正常的血糖代谢所必需的。在高危孕妇中,β细胞 未能补偿母亲的胰岛素抵抗,导致胰岛素不足和妊娠期糖尿病。尽管如此, β细胞如何补偿孕期母亲的胰岛素抵抗以及是什么导致β细胞衰竭 人们对GDM知之甚少。为了破译β细胞对妊娠的补偿机制,我们确定了 整合胰岛素的关键转录因子FOXO1对β细胞质量和功能的孕期调节 细胞新陈代谢、存活、增殖和分化的信号和营养线索。我们发现β-CELL Foxo1的表达明显上调,与β细胞代偿的生理诱导相一致 在怀孕期间的小鼠身上。此外,我们还发现β细胞FoxO1缺乏症易使怀孕的女性 小鼠对GDM的作用,表现为诱导糖耐量受损、血糖水平升高和 怀孕期间葡萄糖刺激的胰岛素分泌减少。这些新数据强调了 Foxo1调节β细胞质量和功能随妊娠的适应性变化,刺激 FoxO1基因失控可能是母体胰岛素抵抗和β细胞之间缺失环节的假说 妊娠期糖尿病代偿失调。为了解决这一假设,我们将使用严格的体内和体外研究来 FoxO1在整合妊娠激素信号以适应β细胞团变化中的作用 以及怀孕期间的功能。我们将确定FOXO_1增强β-细胞的机制 母鼠对母体胰岛素抵抗的补偿。此外,我们还将确定其机制。 β细胞FoxO1缺乏如何导致β细胞失代偿,促进妊娠期糖尿病的发生发展。 该项目的完成将加深我们对孕期β细胞对母体代偿的理解 胰岛素抵抗,为β细胞失代偿和妊娠期糖尿病提供了新的机制见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HENGJIANG HENRY DONG其他文献

HENGJIANG HENRY DONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HENGJIANG HENRY DONG', 18)}}的其他基金

FoxO1 in Gestational Diabetes
FoxO1 在妊娠糖尿病中的作用
  • 批准号:
    10263260
  • 财政年份:
    2020
  • 资助金额:
    $ 38.95万
  • 项目类别:
FoxO1 in Gestational Diabetes
FoxO1 在妊娠糖尿病中的作用
  • 批准号:
    10656362
  • 财政年份:
    2020
  • 资助金额:
    $ 38.95万
  • 项目类别:
FoxO1 in Gestational Diabetes
FoxO1 在妊娠糖尿病中的作用
  • 批准号:
    10418783
  • 财政年份:
    2020
  • 资助金额:
    $ 38.95万
  • 项目类别:
Myeloid FoxO1 in Lipid Metabolism
髓系 FoxO1 在脂质代谢中的作用
  • 批准号:
    10459447
  • 财政年份:
    2019
  • 资助金额:
    $ 38.95万
  • 项目类别:
Myeloid FoxO1 in Lipid Metabolism
髓系 FoxO1 在脂质代谢中的作用
  • 批准号:
    10220965
  • 财政年份:
    2019
  • 资助金额:
    $ 38.95万
  • 项目类别:
Fox01 in Beta-Cell Compensation
Fox01 的 Beta 细胞补偿
  • 批准号:
    8975768
  • 财政年份:
    2014
  • 资助金额:
    $ 38.95万
  • 项目类别:
Fox01 in Beta-Cell Compensation
Fox01 的 Beta 细胞补偿
  • 批准号:
    9187796
  • 财政年份:
    2014
  • 资助金额:
    $ 38.95万
  • 项目类别:
Fox01 in Beta-Cell Compensation
Fox01 的 Beta 细胞补偿
  • 批准号:
    8629313
  • 财政年份:
    2014
  • 资助金额:
    $ 38.95万
  • 项目类别:
Fox01 in Beta-Cell Compensation
Fox01 的 Beta 细胞补偿
  • 批准号:
    8791685
  • 财政年份:
    2014
  • 资助金额:
    $ 38.95万
  • 项目类别:
FoxO6 in Glucose Metabolism
FoxO6 在葡萄糖代谢中的作用
  • 批准号:
    8310118
  • 财政年份:
    2010
  • 资助金额:
    $ 38.95万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 38.95万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 38.95万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了